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Background: About 15 types of human papillomavirus (HPV) are classified as high-risk based on their
epidemiological link with cervical cancer. These HPV types have deferent degrees of oncogenicity and their
distribution among cervical precancers and cancers varies ethnogeographically. HPV58 is rare worldwide but being
found more commonly in East Asia.
Findings: A high prevalence of HPV58 among squamous cell carcinoma has been reported from China (28% in
Shanghai, 10% in Hong Kong and 10% in Taiwan) and other countries in East Asia including Korea (16%) and Japan
(8%). HPV58 ranks the third in Asia overall, but contributes to only 3.3% of cervical cancers globally. The reasons for
a difference in disease attribution may lie on the host as well as the virus itself. HLA-DQB1*06 was found to
associate with a higher risk of developing HPV58-positive cervical neoplasia in Hong Kong women, but not
neoplasia caused by other HPV types. An HPV58 variant (E7 T20I, G63S) commonly detected in Hong Kong was
found to confer a 6.9-fold higher risk of developing cervical cancer compared to other variants. A study involving
15 countries/cities has shown a predilection in the distribution of HPV58 variant lineages. Sublineage A1, the
prototype derived from a cancer patient in Japan, was rare worldwide except in Asia.
Conclusions: HPV58 accounts for a larger share of disease burden in East Asia, which may be a result of differences
in host genetics as well as the oncogenicity of circulating variants. These unique characteristics of HPV58 should be
considered in the development of next generation vaccines and diagnostic assays.Disease burden of cervical cancer
Human papillomavirus (HPV) plays a necessary, though
insufficient, role in the development of cervical cancer,
which is the third most common cancer in women world-
wide, just following breast and colorectal cancers [1,2]. It
has been estimated that about 530 000 new cases and 275
000 deaths from the disease occurred in 2008. The inci-
dence of cervical cancer varies dramatically across the
world, which is mainly related to the availability and acces-
sibility of cervical screening programs. Most places in
South America and South and West Africa have an age-
standardized incidence above 20 per 100 000 women per
year, and some places in these regions have reached 40 per
100 000 women per year. In contrast, the age-standardized
incidence rates were below 10 per 100 000 women per year
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also varies substantially with 9.6 per 100 000 women per
year in East Asia, 15.8 per 100 000 women per year in
South-Eastern Asia, 24.6 per 100 000 women per year in
South-Central Asia and 4.5 per 100 000 women per year
in Western Asia [2].HPV and cervical cancer
Papillomaviruses have a small double-stranded DNA
genome of about 8 kb long. To date, more than 120 types
of HPV have been well characterized, of which about 40
types can infect the genital tract [3]. About 15 types of
these genital (mucosal) HPV are classified as “high-risk” be-
cause of their oncogenic or possible oncogenic properties
either demonstrated by in-vitro biochemical studies or in-
ferred from epidemiological observations [4,5]. Two early
proteins, E6 and E7, are the main oncoproteins encoded by
high-risk HPV [6,7]. E6 protein binds to the tumour suppres-
sor protein p53 in associate with the E6-associated protein
(E6-AP). Overexpression of E6 results in the degradation ofis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ment of foreign DNA integration and activation of telomer-
ase. E7 binds to retinoblastoma protein (Rb) and Rb-related
pocket proteins resulting in inactivation of Rb-related pocket
proteins, activation of cyclins, inhibition of cyclin-dependent
kinase inhibitors, and enhancement of foreign DNA integra-
tion and mutagenesis.Distribution of HPV types
HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 and 59 are
regarded as high-risk types [4,8]. HPV16 and HPV18 con-
tribute to most cervical cancers, accounting respectively
for about 59% and 13% of squamous cell carcinoma, and
36% and 37% of adeno/adenosquamous carcinoma world-
wide [9]. While there is little variation in the prevalence of
HPV16 and HPV18 among cervical cancers across the
world, the contribution of other types varies geographic-
ally. The currently available prophylactic vaccines target
two high-risk types, HPV16 and HPV18. The efficacy of
these vaccines is mainly type-specific, although some
cross-type protection has been observed especially for the
bi-valent vaccine (Cervarix®, GlaxoSmithKline Biologicals)
[10]. Therefore, variation in the distribution of non-vaccine
(non-HPV16/18) types would have an implication on the
design of next generation vaccines.HPV58 in East Asia
Since mid 1990s, a few studies have reported a higher
prevalence of HPV58 among cervical squamous cell
carcinoma cases in the southern and eastern parts of
China [11-13]. With the increase in availability of com-
mercial assays for the identification of multiple types of
HPV, and the increase in demands on HPV type distribu-
tion data for assessing vaccine cost-effectiveness; a large
amount of data have been generated during the last dec-
ade. At present, there is a strong body of evidence to show
that HPV58 attributes to a substantial proportion of cer-
vical cancers in the eastern and southern parts of China.
For instance, HPV58 was found in 26% of squamous cell
carcinoma in Shanghai [12], 10% in Hong Kong [14] and
10% in Taiwan [15]. These prevalence rates are much
higher than those reported from other parts of the world
[9]. The high prevalence of HPV58 is not limited to Chin-
ese women, but also observed in the ethnogeographically
related populations, particularly Korea (16%) and Japan
(8%) [16,17]. HPV58 ranks the third among cervical cancer
cases from Asia overall [18], but only contributes to 3.3%
globally [19]. Furthermore, HPV58 has also been found in a
relatively higher proportion of precancerous lesions (overall
in 17.2% of cervical intraepithelial neoplasia grade 2/3) in
East Asia [20]. Therefore, monitoring the prevalence of
HPV58 in cervical precancers and invasive cancers in East
Asia would provide an early indicator of HPV typereplacement, if it ever occurs following the widespread ad-
ministration of HPV16/18 vaccines.
Reasons for higher prevalence of HPV58 in East
Asia
The reason for a higher prevalence of HPV58 in East Asia
is still not fully understood. The development of a clone
of tumour cells from an HPV-infected epithelium is a
multi-step process involving multiple factors in which
host genetics is likely to be a main determinant. Our pre-
vious study on Hong Kong women has observed a positive
association between HLA-DQB1*06 and HPV58-positive
cervical intraepithelial neoplasia III/invasive cancers [21].
Of note, this risk association was type-specific and was not
observed for cancers caused by other HPV types.
We have also observed that an HPV58 variant commonly
found in Hong Kong was epidemiologically associated with
a higher oncogenic risk [22]. This variant harboring two
amino acid substitutions, T20I and G63S, in the E7 protein
was found to associate with an odds ratio of 10.14 (95%
confidence interval = 10.14–74.72) for the development of
cervical cancer, which was 6.9-fold higher than HPV58 var-
iants without these sequence variations. The first amino
acid substitution (T20I) is close to the Leu-Xaa-Cys-Xaa-
Glu domain that mediates association with the retinoblast-
oma protein (pRb) and its related proteins, p107 and p130.
The substitution G63S results in a serine which could be
phosphorylated by casein kinase II, and a positive associ-
ation between phosphorylation rate and oncogenic poten-
tial of E7 has been reported [23].
Lineage classification and geographical
distribution
While studies from Hong Kong suggest that the host gen-
etic factors and oncogenicity of circulating variants may
play a critical role in the screwed ethnogeographical distri-
bution of HPV58, further large-scale studies incorporating
data from places with high and low prevalence of HPV58
are crucial to verify the observation and further explore the
association. In this regard, it is instrumental to have a uni-
versally accepted classification system for HPV58 variants.
Recently, two independent studies have reached the same
conclusion and set an essential backbone for future studies
[24,25]. The consensus is to classify HPV58 variants into
four lineages designated as A (sublineages A1 and A2), B
(sublineages B1 and B2), C and D (sublineages D1 and D2).
Based on 401 isolates collected from 15 countries/cities
across the four continents, lineage A was found to be the
most prevalent across all regions [24]. Lineage C was found
to be more frequent in Africa than elsewhere, whereas
lineage D was more prevalent in Africa than in Asia. Of
note, sublineage A1 which represents the prototype derived
from a Japanese patient with cancer was rarely found world-
wide, except in Asia. It is worthwhile to further investigate
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sive cancers in East Asia is due to a higher oncogenicity of
sublineage A1. The study has also identified sequence signa-
tures representing these lineages [24], allowing the conduc-
tion of large–scale molecular epidemiological studies on
HPV58.
Conclusions
The disease impact attributed to HPV58 varies ethno-
geographically. The prevalence of HPV58 among cer-
vical cancers found in East Asia is much higher than
that reported from other parts of the world. This could
be a result of differences in host genetic background as
well as the circulation of HPV58 variants with different
oncogenicity. These unique characteristics of HPV58
should be considered in the development of next gener-
ation vaccines and diagnostic assays.
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